share_log

Vivos Therapeutics | UPLOAD: Others

Vivos Therapeutics | UPLOAD: Others

Vivos Therapeutics | UPLOAD:其他
美股sec公告 ·  04/12 12:56
Moomoo AI 已提取核心訊息
Vivos Therapeutics, Inc., a company listed in the US under the stock code VVOS, has been informed by the United States Securities and Exchange Commission (SEC) that its recently filed Registration Statement on Form S-1 will not undergo review. The statement, filed on April 9, 2024, with the file number 333-278564, was acknowledged by the SEC in a letter addressed to R. Kirk Huntsman, the Chief Executive Officer of Vivos Therapeutics. The SEC's correspondence, dated April 12, 2024, also referenced Rules 460 and 461, which pertain to requests for acceleration of the registration process. The SEC reminded the company and its management of their responsibility to ensure the accuracy and adequacy of their disclosures, regardless of the SEC's level of review or lack thereof. The SEC's Division of Corporation Finance, Office of Industrial Applications and Services, directed any further questions to Jane Park and provided her contact information.
Vivos Therapeutics, Inc., a company listed in the US under the stock code VVOS, has been informed by the United States Securities and Exchange Commission (SEC) that its recently filed Registration Statement on Form S-1 will not undergo review. The statement, filed on April 9, 2024, with the file number 333-278564, was acknowledged by the SEC in a letter addressed to R. Kirk Huntsman, the Chief Executive Officer of Vivos Therapeutics. The SEC's correspondence, dated April 12, 2024, also referenced Rules 460 and 461, which pertain to requests for acceleration of the registration process. The SEC reminded the company and its management of their responsibility to ensure the accuracy and adequacy of their disclosures, regardless of the SEC's level of review or lack thereof. The SEC's Division of Corporation Finance, Office of Industrial Applications and Services, directed any further questions to Jane Park and provided her contact information.
美國證券交易委員會(SEC)已通知Vivos Therapeutics, Inc. 是一家在美國上市的公司,股票代碼爲VVOS,該公司最近提交的S-1表格註冊聲明將不接受審查。該聲明於2024年4月9日提交,文件編號爲333-278564,美國證券交易委員會在給Vivos Therapeutics首席執行官柯克·亨斯曼的信中予以確認。美國證券交易委員會在2024年4月12日的信函中還提到了與加快註冊程序的請求有關的第460和461條。美國證券交易委員會提醒該公司及其管理層,無論美國證券交易委員會的審查水平如何,他們都有責任確保披露的準確性和充分性。美國證券交易委員會工業應用與服務辦公室公司財務處向簡·帕克提出了任何進一步的問題,並提供了她的聯繫信息。
美國證券交易委員會(SEC)已通知Vivos Therapeutics, Inc. 是一家在美國上市的公司,股票代碼爲VVOS,該公司最近提交的S-1表格註冊聲明將不接受審查。該聲明於2024年4月9日提交,文件編號爲333-278564,美國證券交易委員會在給Vivos Therapeutics首席執行官柯克·亨斯曼的信中予以確認。美國證券交易委員會在2024年4月12日的信函中還提到了與加快註冊程序的請求有關的第460和461條。美國證券交易委員會提醒該公司及其管理層,無論美國證券交易委員會的審查水平如何,他們都有責任確保披露的準確性和充分性。美國證券交易委員會工業應用與服務辦公室公司財務處向簡·帕克提出了任何進一步的問題,並提供了她的聯繫信息。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息